Ozmosi | PTX-022 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

PTX-022

Alternative Names: ptx-022, ptx022, ptx 022
Clinical Status: Active
Latest Update: 2024-08-29
Latest Update Note: Clinical Trial Update

Product Description

PTX-022 is a novel formulation of rapamycin which leverages Palvellas QTORIN technology.

Mechanisms of Action: TCR Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Palvella Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PTX-022

Countries in Clinic: United Kingdom, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Pachyonychia Congenita

Phase 2: Basal Cell Carcinoma|Basal Cell Nevus Syndrome

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT04893486

CODY

P2

Completed

Basal Cell Nevus Syndrome|Basal Cell Carcinoma

2023-03-13

12%

2024-08-30

Primary Endpoints

NCT05643872

PALV-08

P3

Recruiting

Pachyonychia Congenita

2023-10-01

23%

2025-08-27

Primary Endpoints|Treatments